性激素相关药物对前列腺增生作用的研究进展  

Advances in study on the effects of sex hormone-related drugs on benign prostatic hyperplasia

作　　者：刘浩然 黄国帅 沈一峰 刘昊鹏 袁和兴[1] LIU Haoran;HUANG Guoshuai;SHEN Yifeng;LIU Haopeng;YUAN Hexing(Department of Urinary Surgery,the First Affiliated Hospital of Soochow University,Jiangsu,Suzhou 215006,China)

机构地区：[1]苏州大学附属第一医院泌尿外科,江苏苏州215006

出　　处：《中国医药科学》2022年第23期79-82,88,共5页China Medicine And Pharmacy

摘　　要：前列腺增生(BPH)是老年男性最常见的疾病之一,可导致下尿路症状(LUTS)等多种不适。目前普遍认为雄激素和雌激素在BPH的发生发展过程中起关键作用。2型5α还原酶抑制剂(5-ARIs)通过减少血清中双氢睾酮浓度抑制前列腺增大,是目前临床上治疗BPH的主要用药之一,但常引起阳痿、精量减少、男性乳房发育等副作用,且部分患者接受该药治疗后病情仍持续进展。本文总结了近年来国内外学者针对性激素相关药物在抑制BPH进展方面的研究成果,以期为BPH的性激素理论研究及相关药物研发提供新思路。Benign prostatic hyperplasia(BPH)is one of the most common diseases in elderly men,which can lead to a variety of discomforts collectively known as lower urinary tract symptoms(LUTS).It is now universally accepted that androgens and estrogens play a critical role in the development and progression of BPH.One of the main drugs currently used in the clinical treatment of BPH,type 25α-reductase inhibitors(5-ARIs),can inhibit prostate enlargement by decreasing serum dihydrotestosterone concentrations,but the side effects such as impotence,reduced semen volume,and gynecomastia are common and unavoidable,and some patients still suffer from the disease progression even after receiving this drug.Therefore,this review summarizes the study results of domestic and foreign scholars on sex hormone-related drugs in inhibiting the progression of BPH in recent years,aiming to provide new ideas for the study of BPH-related sex hormone theory and the research and development of related drugs.

关 键 词：前列腺增生 性激素 药物治疗 研究进展 

分 类 号：R697.3[医药卫生—泌尿科学]